Pacritinib-Based Salvage Therapy in High-Risk Polycythaemia Vera With Recurrent Arterial and Venous Thrombosis After Hydroxyurea and Ruxolitinib: A Case Report. (PubMed, Case Rep Hematol) - Oct 18, 2026 - "In February 2025, ruxolitinib was replaced with pacritinib 200 mg twice daily while hydroxyurea and warfarin were continued. This case describes a patient with high-risk, refractory PV and recurrent arterial and venous thrombosis in whom pacritinib-based salvage therapy was associated with improved HCT control, cessation of venesection and absence of further thrombosis during follow-up. Although off-label and hypothesis-generating, this experience supports further evaluation of pacritinib in selected patients with treatment-challenging PV."
JAK2V617F • Journal • Cardiovascular • Hematological Disorders • Myocardial Infarction • Polycythemia Vera • Thrombosis
|